BeiGene is a biotechnology company dedicated to oncology, focused on scientific excellence and the rapid development of cancer treatments. The company employs approximately 12,000 people, including over 1,200 researchers, and operates across six continents in 45+ countries and regions.
Its technical domains include oncology, hematology, solid tumors, protein degradation, CDACs, and antibody drug conjugates. BeiGene has initiated 175+ clinical trials, enrolled over 30,000 patients, and gained regulatory approval for multiple internal oncology medicines in 75+ countries.
The company culture prioritizes patients first, driving excellence, bold ingenuity, and collaborative spirit with non-hierarchical teamwork. Its global scale encompasses over 45 office locations, supporting research and commercial operations.
